Strong operating performance for Roche in 2009, Roche

Release Date: 2010-02-03

Record sales, double-digit growth in operating profit and Core Earnings per share – Dividend increase by 20% to 6.00 Swiss francs proposed

Severin Schwan, CEO of Roche, comments on the Group’s 2009 results: “In a turbulent external environment Roche performed extraordinarily well. Sales by both Pharma and Diagnostics grew twice as fast as their respective markets. Core Earnings per share grew even more strongly than sales. And we have layed the foundation for future growth: Our Pharma pipeline now comprises 10 new molecular entities in late-stage development - which is remarkable by any standards in our industry.”

Speaking of the Genentech integration, Schwan said: "Bringing Genentech fully into the Roche Group is a major step on the road to creating a stronger, even more innovative organisation."

Type:	NORMAL
Company:	Roche
Country:	Switzerland